Tags

Type your tag names separated by a space and hit enter

Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.

Abstract

This study was performed to assess whether patients with Parkinson's disease (PD)develop cognitive and psychiatric impairments more frequently during therapy with continuous subcutaneous apomorphine infusion (CAI) compared to the standard oral treatment. Thirty consecutive PD patients with severe motor fluctuations were included. Of them, 12 patients received the CAI treatment, while the remaining 18 continued the treatment with oral dopaminergic drugs. The two groups were evaluated with neuropsychological,psychiatric and motor tests at baseline and after two years. The off-awake daily duration and the levodopa dosage were significantly reduced in the patients infused with apomorphine.In comparison with the baseline evaluation, the neuropsychiatric assessment did not change in either of groups at the follow-up, except for a significant improvement of mood in the CAI treated group.

Authors+Show Affiliations

Department of Neuroscience, Psychiatry and Anesthesiology,I-98125 Messina, Italy. morgante@unime.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

15207426

Citation

Morgante, L, et al. "Continuous Apomorphine Infusion (CAI) and Neuropsychiatric Disorders in Patients With Advanced Parkinson's Disease: a Follow-up of Two Years." Archives of Gerontology and Geriatrics. Supplement, 2004, pp. 291-6.
Morgante L, Basile G, Epifanio A, et al. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. Arch Gerontol Geriatr Suppl. 2004.
Morgante, L., Basile, G., Epifanio, A., Spina, E., Antonini, A., Stocchi, F., Di Rosa, E., Martino, G., Marconi, R., La Spina, P., Nicita-Mauro, V., & Di Rosa, A. E. (2004). Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. Archives of Gerontology and Geriatrics. Supplement, (9), 291-6.
Morgante L, et al. Continuous Apomorphine Infusion (CAI) and Neuropsychiatric Disorders in Patients With Advanced Parkinson's Disease: a Follow-up of Two Years. Arch Gerontol Geriatr Suppl. 2004;(9)291-6. PubMed PMID: 15207426.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. AU - Morgante,L, AU - Basile,G, AU - Epifanio,A, AU - Spina,E, AU - Antonini,A, AU - Stocchi,F, AU - Di Rosa,E, AU - Martino,G, AU - Marconi,R, AU - La Spina,P, AU - Nicita-Mauro,V, AU - Di Rosa,A E, PY - 2004/6/23/pubmed PY - 2004/10/22/medline PY - 2004/6/23/entrez SP - 291 EP - 6 JF - Archives of gerontology and geriatrics. Supplement JO - Arch Gerontol Geriatr Suppl IS - 9 N2 - This study was performed to assess whether patients with Parkinson's disease (PD)develop cognitive and psychiatric impairments more frequently during therapy with continuous subcutaneous apomorphine infusion (CAI) compared to the standard oral treatment. Thirty consecutive PD patients with severe motor fluctuations were included. Of them, 12 patients received the CAI treatment, while the remaining 18 continued the treatment with oral dopaminergic drugs. The two groups were evaluated with neuropsychological,psychiatric and motor tests at baseline and after two years. The off-awake daily duration and the levodopa dosage were significantly reduced in the patients infused with apomorphine.In comparison with the baseline evaluation, the neuropsychiatric assessment did not change in either of groups at the follow-up, except for a significant improvement of mood in the CAI treated group. SN - 0924-7947 UR - https://www.unboundmedicine.com/medline/citation/15207426/Continuous_apomorphine_infusion__CAI__and_neuropsychiatric_disorders_in_patients_with_advanced_Parkinson's_disease:_a_follow_up_of_two_years_ L2 - https://medlineplus.gov/depression.html DB - PRIME DP - Unbound Medicine ER -